論文（英文）

• Sasaki S, Nagasaki T, Oba K, Akiyoshi T, Mukai T, Yamaguchi T, Fukunaga Y, Fujimoto Y. Risk factors for outlet obstruction after laparoscopic surgery and diverting ileostomy for rectal cancer. Surg Today. 2020 Aug 4. doi: 10.1007/s00595-020-02096-2. Online ahead of print
• Ogiya R, Niikura N, Kumamaru H, Takeuchi Y, Okamura T, Kinoshita T, Aogi K, Anan K, Iijima K, Ishida T, Iwamoto T, Kawai M, Kojima Y, Sakatani T, Sagara Y, Hayashi N, Masuoka H, Yoshida M, Miyata H, Tsuda H, Imoto S, Jinno H. Breast cancer survival among Japanese individuals and US residents of Japanese and other origins: A comparative registry-based study. Breast Cancer Res Treat. 2020; 184(2): 585-596.
• Hagiwara Y, Kawahara T, Shiroiwa T. What is a valid mapping algorithm in cost-utility analyses? A response from a missing data perspective. Value Health. 2020;23:1218–1224.
• Miyo M, Kato T, Yoshino T, Yamanaka T, Bando H, Satake H, Yamazaki K, Taniguchi H, Oki E, Kotaka M, Oba K, Miyata Y, Muro K, Komatsu Y, Baba H, Tsuji A. Protocol of the QUATTRO-II study: a multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab as a first-line treatment in patients with metastatic colorectal cancer. BMC Cancer. 2020 Jul 23;20(1):687. doi: 10.1186/s12885-020-07186-5.
• Fukayama M, Yoshizaki A, Fukasawa T, Ebata S, Kuzumi A, Yoshizaki-Ogawa A, Asano Y, Oba K, Sato S. Interleukin (IL)-17F and IL-17E are related to fibrosis and vasculopathy in systemic sclerosis. J Dermatol. 2020 Jul 19. doi: 10.1111/1346-8138.15508. Online ahead of print.
• Satake H, Kato T, Oba K, Kotaka M, Kagawa Y, Yasui H, Nakamura M, Watanabe T, Matsumoto T, Kii A, Terazawa T, Makiyama A, Takano N, Yokota M, Okita Y, Matoba K, Hasegawa H, Tsuji A, Komatsu Y, Yoshino T, Yamazaki K, Mishima H, Oki E, Nagata N, Sakamoto J. Phase Ib/II Study of Biweekly TAS-102 in Combination with Bevacizumab for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies (BiTS study). Oncologist. 2020 Jul 14. doi: 10.1634/theoncologist.2020-0643. Online ahead of print.
• Miyasato Y, Oba K, Yasuno S, Matsuyama Y, Masuda I. Associations between visceral obesity and renal impairment in health checkup participants: a retrospective cohort study. Clin Exp Nephrol. 2020 Jul 1. doi: 10.1007/s10157-020-01921-9. Online ahead of print.
• Motoki H, Masuda I, Yasuno S, Oba K, Shoin W, Usami S, Saito Y, Waki M, Komatsu M, Ueshima K, Nakagawa Y, Son C, Yonemitsu S, Hiramitsu S, Konda M, Onishi K, Kuwahara K. Rationale and design of the EMPYREAN study. ESC Heart Fail. 2020 Jun 23. doi: 10.1002/ehf2.12825. Online ahead of print.
• Hagiwara Y, Shinozaki T, Mukai H, Matsuyama Y. Sensitivity analysis for subsequent treatments in confirmatory oncology clinical trials: a two-stage stochastic dynamic treatment regime approach. Biometrics. 2020. doi: 10.1111/biom.13296. Online ahead of print.
• Ikeda T, Kato A, Bougaki M, Araki Y, Ohata T, Kawashima S, Imai Y, Ninagawa J, Oba K, Chang K, Uchida K, Yamada Y. A retrospective review of 10-year trends in general anesthesia for cesarean delivery at a university hospital: the impact of a newly launched team on obstetric anesthesia practice. BMC Health Serv Res. 2020 May 13;20(1):421.
• Ebata S, Yoshizaki A, Fukasawa T, Asano Y, Oba K, Sato S. Rapid decrease of serum surfactant protein-D levels predicts the reactivity of rituximab therapy in systemic sclerosis-associated interstitial lung disease. J Dermatol. 2020 May 7. doi: 10.1111/1346-8138.15379. Online ahead of print.
• Furihata K, Tsuchikawa M, Miwa T, Naito Y, Oba K, Sakagami M. Efficacy and Safety of Polaprezinc (Zinc Compound) on Zinc Deficiency: A Systematic Review and Dose-Response Meta-Analysis of Randomized Clinical Trials Using Individual Patient Data. Nutrients. 2020 Apr 17;12(4):E1128. doi: 10.3390/nu12041128.
• Kozuma K, Kozuma K, Shinozaki T, Kashiwabara K, Oba K; Xience P. M. S. Group; PROMUS Element/Element Plus P. M. S. Group, Matsuyama Y. Multivariable Prediction Model to Estimate the Probability of Restenosis at Proximal Edge After 2nd-generation Drug-Eluting-Stent Implantation: Development and Internal Validation Using a Quantitative Coronary Angiography From the Post-Marketing Surveillance Studies of Everolimus-Eluting Stent in Japan. Cardiovasc Interv Ther. 2020 Apr 18.
• Kumazu Y, Oba K, Hayashi T, Yamada T, Hara K, Osakabe H, Shimoda Y, Nakazono M, Nagasawa S, Rino Y, Masuda M, Ogata T, Yoshikawa T, Oshima T. Relationship Between the Waiting Times for Surgery and Survival in Patients with Gastric Cancer. World J Surg. 2020 Apr;44(4):1209-1215.
• Fujieda Y, Maeda H, Oba K, Okamoto K, Fukudome I, Shiga M, Kawanishi Y, Akimori T, Kuroiwa H, Nishimoto H, Namikawa T, Murakami I, Kobayashi M, Hanazaki K. Lymph node retrieval after colorectal cancer surgery: a comparative study of the efficacy between the conventional manual method and a new fat dissolution method. Surg Today. 2020 Jan 7.
• Tanaka Y, Oba K, Takeuchi T. Response to: 'Comment on 'Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial' by Tanaka et al' by Berkhout et al. Ann Rheum Dis. 2019 Dec 9:annrheumdis-2019-216593.
• Yamaguchi H, Takezako N, Ohashi K, Oba K, Kumagai T, Kozai Y, Wakita H, Yamamoto K, Fujita A, Igarashi T, Yoshida C, Ohyashiki K, Okamoto S, Sakamoto J, Sakamaki H, Inokuchi K. Treatment-free remission after first-line dasatinib treatment in patients with chronic myeloid leukemia in the chronic phase: the D-NewS Study of the Kanto CML Study Group. Int J Hematol. 2020 Mar;111(3):401-408.
• Suzuki S, Akiyoshi T, Oba K, Otsuka F, Tominaga T, Nagasaki T, Fukunaga Y, Ueno M. Comprehensive Comparative Analysis of Prognostic Value of Systemic Inflammatory Biomarkers for Patients with Stage II/III Colon Cancer. Ann Surg Oncol. 2020 Mar;27(3):844-852.
• Ikeda T, Yamauchi Y, Uchida K, Oba K, Nagase T, Yamada Y. Reference value for expiratory time constant calculated from the maximal expiratory flow-volume curve. BMC Pulm Med. 2019 Nov 11;19(1):208.
• Tanaka Y, Oba K, Koike T, Miyasaka N, Mimori T, Takeuchi T, Hirata S, Tanaka E, Yasuoka H, Kaneko Y, Murakami K, Koga T, Nakano K, Amano K, Ushio K, Atumi T, Inoo M, Hatta K, Mizuki S, Nagaoka S, Tsunoda S, Dobashi S, Horie N, Sato N. Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomized controlled trial. Ann Rheum Dis 2020; 79(1):94-102.

TOP